- Home
- MRSN vs AIRJ Comparison
MRSN vs AIRJ Comparison
Compare MRSN & AIRJ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRSN
- AIRJ
- Stock Information
- Founded
- MRSN 2001
- AIRJ N/A
- Country
- MRSN United States
- AIRJ United States
- Employees
- MRSN N/A
- AIRJ N/A
- Industry
- MRSN Biotechnology: Pharmaceutical Preparations
- AIRJ
- Sector
- MRSN Health Care
- AIRJ
- Exchange
- MRSN Nasdaq
- AIRJ NYSE
- Market Cap
- MRSN 252.0M
- AIRJ 285.0M
- IPO Year
- MRSN 2017
- AIRJ N/A
- Fundamental
- Price
- MRSN $1.86
- AIRJ $10.13
- Analyst Decision
- MRSN Buy
- AIRJ
- Analyst Count
- MRSN 6
- AIRJ 0
- Target Price
- MRSN $6.00
- AIRJ N/A
- AVG Volume (30 Days)
- MRSN 1.1M
- AIRJ 90.2K
- Earning Date
- MRSN 11-13-2024
- AIRJ 11-13-2024
- Dividend Yield
- MRSN N/A
- AIRJ N/A
- EPS Growth
- MRSN N/A
- AIRJ N/A
- EPS
- MRSN N/A
- AIRJ 4.07
- Revenue
- MRSN $34,837,000.00
- AIRJ N/A
- Revenue This Year
- MRSN N/A
- AIRJ N/A
- Revenue Next Year
- MRSN N/A
- AIRJ N/A
- P/E Ratio
- MRSN N/A
- AIRJ $2.78
- Revenue Growth
- MRSN N/A
- AIRJ N/A
- 52 Week Low
- MRSN $1.22
- AIRJ $4.94
- 52 Week High
- MRSN $6.28
- AIRJ $49.11
- Technical
- Relative Strength Index (RSI)
- MRSN 42.16
- AIRJ 69.19
- Support Level
- MRSN $1.93
- AIRJ $8.52
- Resistance Level
- MRSN $2.81
- AIRJ $11.60
- Average True Range (ATR)
- MRSN 0.24
- AIRJ 0.90
- MACD
- MRSN -0.05
- AIRJ 0.18
- Stochastic Oscillator
- MRSN 7.79
- AIRJ 71.07
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs includes XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.
About AIRJ MONTANA TECHNOLOGIES CORP
Montana Technologies Corp is engaged in transformational technology that provides significant energy efficiency gains in air conditioning and comfort cooling applications, as well as a potential source of potable water, all through its proprietary "AirJoule" unit.